NO965231L - FLT4-reseptor tyrosinkinase og dens anvendelse ved diagnose og terapi - Google Patents

FLT4-reseptor tyrosinkinase og dens anvendelse ved diagnose og terapi

Info

Publication number
NO965231L
NO965231L NO965231A NO965231A NO965231L NO 965231 L NO965231 L NO 965231L NO 965231 A NO965231 A NO 965231A NO 965231 A NO965231 A NO 965231A NO 965231 L NO965231 L NO 965231L
Authority
NO
Norway
Prior art keywords
diagnosis
therapy
tyrosine kinase
receptor tyrosine
flt4 receptor
Prior art date
Application number
NO965231A
Other languages
English (en)
Other versions
NO965231D0 (no
NO319383B1 (no
Inventor
Kari Alitalo
Arja Kaipainen
Jaana Korhonen
Tuija Mustonen
Katri Pajusola
Marja-Terttu Matikainen
Paeivi Karnani
Original Assignee
Kari Alitalo
Arja Kaipainen
Jaana Korhonen
Tuija Mustonen
Katri Pajusola
Matikainen Marja Terttu
Paeivi Karnani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kari Alitalo, Arja Kaipainen, Jaana Korhonen, Tuija Mustonen, Katri Pajusola, Matikainen Marja Terttu, Paeivi Karnani filed Critical Kari Alitalo
Publication of NO965231L publication Critical patent/NO965231L/no
Publication of NO965231D0 publication Critical patent/NO965231D0/no
Publication of NO319383B1 publication Critical patent/NO319383B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19965231A 1994-06-09 1996-12-06 FLT4-reseptor tyrosinkinase og dens anvendelse ved diagnose og terapi NO319383B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25775494A 1994-06-09 1994-06-09
PCT/FI1995/000337 WO1995033772A1 (en) 1994-06-09 1995-06-09 Flt4 receptor tyrosine kinase and its use in diagnosis and therapy

Publications (3)

Publication Number Publication Date
NO965231L true NO965231L (no) 1996-12-06
NO965231D0 NO965231D0 (no) 1996-12-06
NO319383B1 NO319383B1 (no) 2005-07-25

Family

ID=22977612

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19965231A NO319383B1 (no) 1994-06-09 1996-12-06 FLT4-reseptor tyrosinkinase og dens anvendelse ved diagnose og terapi

Country Status (14)

Country Link
EP (1) EP0807124B1 (no)
JP (4) JP3723210B2 (no)
AT (1) ATE326484T1 (no)
AU (1) AU694524B2 (no)
CA (1) CA2192235C (no)
DE (1) DE69534996T2 (no)
DK (1) DK0807124T3 (no)
ES (1) ES2263152T3 (no)
FI (1) FI964862A7 (no)
MX (1) MX9606218A (no)
NO (1) NO319383B1 (no)
NZ (1) NZ288235A (no)
PT (1) PT807124E (no)
WO (1) WO1995033772A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
FR2783325A1 (fr) * 1998-09-11 2000-03-17 Inst Nat Sante Rech Med Moyens pour le controle de la regulation negative d'une activation transmise par un rtk
ATE489108T1 (de) * 1998-10-09 2010-12-15 Vegenics Ltd Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
EP1553414A1 (en) * 1999-04-13 2005-07-13 Medarex, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
CA2370237A1 (en) * 1999-04-13 2000-10-19 Northwest Biotherapeutics, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6599717B1 (en) * 1999-10-01 2003-07-29 Exelixis, Inc. Invertebrate vascular endothelial growth factor receptor
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
WO2007138143A2 (es) * 2006-05-29 2007-12-06 Consejo Superior De Investigaciones Cientificas Anticuerpos monoclonales anti-colina quinasa alfa y su uso en técnicas analíticas, de diagnóstico del cáncer y en la preparación de medicamentos
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0620826A1 (en) * 1992-01-09 1994-10-26 Helsinki University Holding, Ltd. Tie, a novel endothelial cell receptor tyrosine kinase
AU687727B2 (en) * 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists

Also Published As

Publication number Publication date
JP3723210B2 (ja) 2005-12-07
AU2738895A (en) 1996-01-04
ATE326484T1 (de) 2006-06-15
WO1995033772A1 (en) 1995-12-14
JPH10500858A (ja) 1998-01-27
JP2005139199A (ja) 2005-06-02
EP0807124A1 (en) 1997-11-19
FI964862L (fi) 1997-02-10
FI964862A0 (fi) 1996-12-04
NZ288235A (en) 1999-05-28
DK0807124T3 (da) 2006-08-28
EP0807124B1 (en) 2006-05-17
DE69534996T2 (de) 2007-05-10
CA2192235A1 (en) 1995-12-14
CA2192235C (en) 2011-02-15
MX9606218A (es) 1998-02-28
ES2263152T3 (es) 2006-12-01
JP2012193191A (ja) 2012-10-11
PT807124E (pt) 2006-08-31
FI964862A7 (fi) 1997-02-10
DE69534996D1 (de) 2006-06-22
AU694524B2 (en) 1998-07-23
NO965231D0 (no) 1996-12-06
NO319383B1 (no) 2005-07-25
JP2009102415A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
NO965231D0 (no) FLT4-reseptor tyrosinkinase og dens anvendelse ved diagnose og terapi
MX9707889A (es) Metodo y dispositivo para diagnosticar y distinguir dolor de pecho en inicio temprano del mismo.
EP0914155A4 (en) PROSTATE SPECIFIC MEMBRANE ANTIGEN MONOCLONAL ANTIBODIES
ATE254765T1 (de) Blutgerinnsel-detektor
IL121659A0 (en) Determining cPSA in a blood sample
WO2002074789A3 (en) Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection
DE69839876D1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
NO177463C (no) STLV-III-beslektede polypeptider, diagnostiske prövesett og in vitro analysefremgangsmåte for påvisning av anti-HIV-2-antistoffer i kroppsvæskepröve
ATE433575T1 (de) Neurotransmission-störungen
ES2189254T3 (es) Dosificado inmunologico que permite detectar los anticuerpos igm especificos del citomegalovirus humano.
FI943921A0 (fi) Bestaemning av fri och komplexbunden trypsinogen-2
WO1990008956A1 (en) Detection of human tissue factor activator
ATE208041T1 (de) A-protein als diagnostikum für krebs
RU95116716A (ru) Способ лабораторной диагностики вич-инфекции
IT1309442B1 (it) Procedimento di rivelazione immunoenzimatica di un complesso antigene/anticorpo primario e kit diagnostico per la sua attuazione.
RU2000127064A (ru) Способ диагностики развития дегенеративно-дистрофических поражений позвоночника у детей
CA2173834A1 (en) Monoclonal antibodies to thymidine kinase isozymes